Source BioScience Launches New Overnight Service in Oxford
Published: Oct 31, 2011
The Overnight Service will now be available to research teams in and around Oxford, with customers receiving their sequencing results by 9am the next day, including Saturdays, at no extra cost.
The DNA sequencing and data analysis service has been operational since June, when it was launched in London, Cambridge and the Midlands and most recently in Berlin, Germany. The service targets the life sciences research sector with the offer of free sample collection and super fast delivery of results, combining Source BioScience’s world class sequencing capabilities with its unique SpeedREAD™ automated data delivery system.
Dr Nick Ash, CEO at Source BioScience, commented: “Our Overnight Service continues to set new standards in sequencing services and can play a major part in reducing downtime in research projects by delivering results in a timely fashion. We are delighted to extend the service to our Oxford customers.”
He added, “The Overnight Service is already having a very positive impact on our business, with a significant increase in sequencing volumes since its launch in June 2011. We look forward to broadening the reach of this service in due course, enabling more customers to access the benefits of overnight sequencing, and we will be providing an update on this part of our business at the Q3 results next month.”
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO
Tel: +44 (0) 115 973 9010
College Hill (PR Agency to Source BioScience)
Melanie Toyne Sewell/ Dimithri Wignarajah
Tel: +44 (0)207 457 2020
Mob: +44 7890 022 814
About Source BioScience:
Source BioScience plc (LSE: SBS) is an international diagnostics and genetic analysis business serving the healthcare and research markets. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. The Company is a trusted provider of a complete range of sophisticated microarray, next generation and conventional sequencing services. GLP, GCP and CPA accreditations make the sequencing offerings also very attractive for applications in regulatory studies or clinical settings. Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. The Group has its headquarters in Nottingham, UK. Further information about Source BioScience can be found at www.sourcebioscience.com